ClinicalTrials.gg
RecruitingNCT06830889Updated Jan 22, 2026

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

A Phase 3 interventional study of BL-M07D1 and T-DM1 in HER2-positive Breast Cancer, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,450
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd. — 15 open to participants now, 20 under way, 7 of them phase 3. Breast Neoplasms · Sichuan Biokin Pharmaceutical Co., Ltd..

Planned enrollment
Largest of 22
1,450 · median 83
Started
2025
with 4 others
Phase 3
6 of 22
4 open now
Primary completion
2031-10
later than 19 of 19 live
Registered
15th of 22
by date

Among the 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd., this one has the largest planned enrollment, is one of 5 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 19 of the 19 other live ones, and was the 15th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Breast Neoplasms by Sichuan Biokin Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form voluntarily and follow the protocol requirements;
  2. Women aged ≥18 years and ≤75 years at the time of written informed consent;
  3. Expected survival time ≥6 months;
  4. Patients with confirmed -positive invasive breast cancer;
  5. Before therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system;
  6. The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol;
  7. Previous neoadjuvant therapy should meet the prescribed treatment conditions;
  8. Had received radical mastectomy;
  9. Determine hormone receptor (HR) status;
  10. The interval between radical surgery and randomization was at least 3 weeks and at most 12 weeks;
  11. score 0 or 1;
  12. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by v5.0;
  13. No blood transfusion within 14 days before the first use of the study drug and no use of colony-stimulating factors were allowed;
  14. For premenopausal women with , a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients should use adequate and highly effective during the entire treatment cycle and for 7 months after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. A diagnosis of stage IV breast cancer was made;
  2. Bilateral breast cancer;
  3. Any previous history of breast cancer (unilateral or contralateral) except for lobular carcinoma in situ (LCIS);
  4. Evidence of residual disease or recurrent or metastatic disease after therapy and surgery;
  5. Other primary diagnosed within 5 years before the first dose;
  6. Received previous -ADC, immunotherapy, or other antitumor biological therapy;
  7. Subjects are participating in other clinical studies and receiving anti-tumor treatment;
  8. Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose > 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride > 480 mg/m2;
  9. History of severe cardiovascular or cerebrovascular disease within six months before screening;
  10. , complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  11. Poorly controlled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
  12. Complicated with pulmonary diseases leading to severe impairment of lung function;
  13. A history of ILD/interstitial pneumonia requiring therapy, current ILD/interstitial pneumonia, or suspected such disease during screening; v5.0 was used to define grade ≥3 pulmonary disease and grade ≥2 radiation pneumonitis;
  14. antibody (HIVAb) positive, active virus infection, liver cirrhosis, or virus infection;
  15. Had a serious infection within 4 weeks before the first dose of study drug; There was active pulmonary inflammation at the time of screening;
  16. Were receiving \&gt within 2 weeks before the first dose; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of therapy;
  17. Patients with a history of severe allergy to recombinant humanized antibodies or to any of the excipents of BL-M07D1;
  18. Known or delayed hypersensitivity to certain components of T-DM1 or similar drugs, or known to T-DM1;
  19. Had a history of or allogeneic stem cell transplantation or organ transplantation;
  20. Have a severe neurological or psychiatric illness;
  21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the ;
  22. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;
  23. Subjects scheduled to receive or within 28 days before the first dose;
  24. Patients with other serious physical and laboratory abnormalities or poor adherence that may increase the risk of participating in the study, or interfere with the results of the study, and patients who were deemed by the investigators to be unsuitable for participation in the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,450 participants (estimated)

Study arms

  • Experimental
    BL-M07D1

    Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: BL-M07D1

  • Active comparator
    T-DM1

    Participants receive T-DM1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: T-DM1

Interventions

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • DrugT-DM1

    Administration by intravenous infusion for a cycle of 3 weeks.

06

What researchers measure

Primary outcomes

  1. Invasive Disease-free Survival (IDFS)

    IDFS refers to the absence of invasive cancer recurrence after breast cancer treatment.

    Time frame: Up to approximately 77 months

Secondary outcomes

  1. Disease-free Survival(DFS)

    DFS is defined as the time from random occurrence of a tumor to recurrence.

    Time frame: Up to approximately 77 months

  2. Distant Recurrence-free Interval (DRFI)

    DRFI is defined as the interval from the date of randomization to the first occurrence of distant recurrence of breast cancer or death due to breast cancer.

    Time frame: Up to approximately 77 months

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.

    Time frame: Up to approximately 77 months

  4. Treatment Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M07D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M07D1.

    Time frame: Up to approximately 77 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2031, 76 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 76 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 17, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Oct 2031
CompletionEst.
Dec 2031
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06830889
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Jun 3, 2025
Primary completion
Oct 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Jan 22, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2 Antibody-drug Conjugate BL-M07D1

Start the discussion